{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT02316106","nct_id":"NCT02316106","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02316106. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Arm A (Long Intense)","type":"EXPERIMENTAL"},{"description":null,"label":"Arm B (Intermediate)","type":"EXPERIMENTAL"},{"description":null,"label":"Arm C (Short Intense)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-06-03","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":123,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"daratumumab","otherNames":[],"type":"DRUG"},{"name":"daratumumab","otherNames":[],"type":"DRUG"},{"name":"daratumumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-04-23","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-06-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants Who Achieved a Complete Response (CR) by International Myeloma Working Group (IMWG) Criteria","timeFrame":"From Cycle 1 Day 1 up to 1.58 years"},{"measure":"Progressive Disease or Death Rate","timeFrame":"From Cycle 1 Day 1 up to 2.07 years"}],"references":[{"citation":"Landgren O, Chari A, Cohen YC, Spencer A, Voorhees PM, Sandhu I, Jenner MW, Smith D, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Vieyra D, Sha L, Li L, Rousseau E, Dennis R, Carson R, Hofmeister CC. Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS. Blood. 2025 Apr 10;145(15):1658-1669. doi: 10.1182/blood.2024025897.","pmid":"39652826","type":"DERIVED"},{"citation":"Chari A, Munder M, Weisel K, Jenner M, Bygrave C, Petrucci MT, Boccadoro M, Cavo M, van de Donk NWCJ, Turgut M, Demirkan F, Karadogan I, Libby E, Kleiman R, Kuppens S, Bandekar R, Neff T, Heuck C, Qi M, Clemens PL, Goldschmidt H. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. Adv Ther. 2021 Feb;38(2):1328-1341. doi: 10.1007/s12325-020-01601-w. Epub 2021 Jan 20.","pmid":"33474705","type":"DERIVED"},{"citation":"Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees P, Estell JA, Sandhu I, Jenner MW, Williams C, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Kuppens S, Bandekar R, Clemens PL, Neff T, Heuck C, Qi M, Hofmeister CC. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020 Jul;34(7):1840-1852. doi: 10.1038/s41375-020-0718-z. Epub 2020 Feb 5.","pmid":"32024950","type":"DERIVED"}],"start_date":{"date":"2015-05-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT02316106"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02316106"}